长效胰岛素类似物长期使用与2型糖尿病女性乳腺癌发病风险
基于英国临床实践研究数据链的人群队列纳入22395例40岁及以上使用长效胰岛素或NPH胰岛素的2型糖尿病女性,随访至2015年2月或乳腺癌诊断。与NPH胰岛素相比,甘精胰岛素与乳腺癌风险升高相关(HR 1.44,95%CI 1.11-1.85),地特胰岛素风险未显著升高(HR 1.17,95%CI 0.77-1.77)。
要点
- 甘精胰岛素与乳腺癌风险升高相关(HR 1.44,95%CI 1.11-1.85)。
- 甘精胰岛素使用5年后(HR 2.23)及超过30张处方后(HR 2.29)风险更高。
- 地特胰岛素与乳腺癌风险无显著升高(HR 1.17,95%CI 0.77-1.77)。
核心结论
- 长期使用甘精胰岛素与2型糖尿病女性乳腺癌风险升高相关。
- 地特胰岛素相关风险仍不确定,因使用者较少。
研究设计与样本
- 基于英国临床实践研究数据链的人群队列,纳入2002年至2012年间接受甘精胰岛素、地特胰岛素或中性鱼精蛋白哈格多恩(NPH)胰岛素治疗的40岁及以上女性。
- 随访至2015年2月或乳腺癌诊断,采用Cox比例风险模型估计调整风险比(HR)及95%CI。
- 队列共22395例接受胰岛素治疗的女性,随访期间发生321例乳腺癌事件,随访最长12年,发病率为3.3/1000人年。
主要发现
- 与NPH胰岛素相比,甘精胰岛素与乳腺癌风险升高相关(HR 1.44,95%CI 1.11-1.85)。
- 甘精胰岛素起始5年后风险升高(HR 2.23,95%CI 1.32-3.77),超过30张处方后风险升高(HR 2.29,95%CI 1.26-4.16)。
- 既往使用过胰岛素者风险尤其升高(HR 1.53,95%CI 1.10-2.12),新使用者中未见风险升高,但新使用者人数较少,不能排除HR为1.81。
- 地特胰岛素相关风险未显著升高(HR 1.17,95%CI 0.77-1.77)。
局限性
- 原文指出地特胰岛素相关风险仍不确定,因该胰岛素使用者较少。
- 原文指出新使用者人数较少,不能排除HR为1.81。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The association between long-acting insulin analogs and increased breast cancer risk is uncertain, particularly with the short follow-up in previous studies. We assessed this risk long term in women with type 2 diabetes. Methods A population-based cohort of women 40 years or older, all of whom were treated with long-acting (glargine, detemir) or neutral protamine Hagedorn (NPH) insulin between 2002 and 2012, was formed using the United Kingdom's Clinical Practice Research Datalink. Women were followed until February 2015 or breast cancer diagnosis. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% CIs of incident breast cancer, comparing long-acting insulin analogs with NPH overall, as well as by duration and cumulative dose. Results The cohort included 22,395 women who received insulin treatment, with 321 incident breast cancer events occurring during up to 12 years of follow-up (incidence rate 3.3 per 1,000 person-years). Compared with NPH insulin, insulin glargine was associated with an increased risk of breast cancer (HR, 1.44; 95% CI, 1.11 to 1.85), mainly increasing 5 years after glargine initiation (HR, 2.23; 95% CI, 1.32 to 3.77) and after > 30 prescriptions (HR, 2.29; 95% CI, 1.26 to 4.16). The risk was particularly elevated among prior insulin users (HR, 1.53; 95% CI, 1.10 to 2.12) but not for new users, which included fewer patients and for which one cannot rule out an HR of 1.81. The risk associated with insulin detemir was not significantly elevated (HR, 1.17; 95% CI, 0.77 to 1.77). Conclusion Long-term use of insulin glargine is associated with an increased risk of breast cancer in women with type 2 diabetes. The risk associated with insulin detemir remains uncertain because there are fewer users of this insulin.
引用
- Wu JW, Azoulay L, Majdan A, et al. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. J Clin Oncol. 2017. PMID: 28953430. doi:10.1200/JCO.2017.73.4491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。